trending Market Intelligence /marketintelligence/en/news-insights/trending/yiz9vkv5yqcdsf8mr1f2_g2 content esgSubNav
In This List

AstraZeneca appoints lung cancer specialist Tony Mok to board

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


AstraZeneca appoints lung cancer specialist Tony Mok to board

AstraZeneca PLC appointed Tony Mok to be a nonexecutive director and a member of its science committee, effective Jan. 1, 2019.

Mok is chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. He is also a nonexecutive director at Hutchison China MediTech Ltd. and a co-founder and the chairman of Sanomics Ltd.

Mok is chair of the International Affair Committee and member of publication committee of ASCO, the American Society of Clinical Oncology.

He has headed multiple international phase 3 trials in lung cancer, his main research interest.

The U.K. drugmaker also confirmed the previously announced retirement of Shriti Vadera, effective Dec. 31.